|
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN TYLENOL W/ CODEINE, ACETAMINOPHEN TYLENOL, ACETAMINOPHEN (OTC) TYLOX, ACETAMINOPHEN TYLOX-325, ACETAMINOPHEN TYMTRAN, CERULETIDE DIETHYLAMINE TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE TZ-3, TIOCONAZOLE (OTC) ** U ** U-CORT, HYDROCORTISONE ACETATE U-GENCIN, GENTAMICIN SULFATE UCEPHAN, SODIUM BENZOATE ULO, CHLOPHEDIANOL HYDROCHLORIDE ULTANE, SEVOFLURANE ULTIVA,...
|
|
|
../2002/21-200_Zelnorm_
Food and Drug Administration • Center for Drug Evaluation and Research Title Search Zelnorm (Tegaserod Maleate) Tablets Company:--Novartis Pharmaceuticals Corporation Application No.:--21-200 Approval Date:-7/24/2002 Approval Letter(s) - Printed Labeling - Medical Review(s)- Part 1 - Part 2 - Part 3 - Part 4 - Chemistry Review(s) - Pharmacology Review(s)- Part...
author: USERNAME
|
|
|
NMEs Approved in CY 2002
NMEs Approved in Calendar Year 2002 - NDA Number Generic Name Trade Name Dosage Form Applicant *Classification Approval Date 21-232 Nitisinone Orfadin Capsule Swedish Orphan -- 1PV 01-18-2002 21-286 Olmesartan Medoxomil Benicar Tablet Sankyo- 1S 04-25-2002 21-344 Fulvestrant Faslodex Injection AstraZeneca 1S 04-25-2002 21-272 Treprostinil Sodium Remodulin Injection United...
author: Susan Daugherty
|
|
|
FDA Drug Approvals List July 2002
- Drug Approvals for July 2002 Definitions and Notes Original New Drug Applications Original New Drug Application # 021409 Approval Date: 26-JUL-02 Trade Name: SINGULAIR Chemical Type: 3 Therapeutic Potential: S Dosage Form: GRANULE Applicant: MERCK RESEARCH LABORATORIES DIV MERCK CO INC Active Ingredient(s): MONTELUKAST SODIUM OTC/RX Status: RX Indication of Use: PROPHYLAXIS/CHRONIC...
|
|
|
Prescription and OTC Drug Product List 8/2002
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE -A- AA ABLE 300MG;30MG N40452 001 AUG 01, 2002 AUG NEWA -A- AA 300MG;60MG N40459 001 AUG 01, 2002 AUG NEWA ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE TABLET; ORAL ACETAMINOPHEN AND PENTAZOCINE HCL -A- AB AMIDE PHARM 650MG;EQ 25MG BASE N76202 001 AUG...
|
|
|
Prescription and OTC Drug Product List 6/2002
-A- + GD SEARLE LLC EQ 500MG BASE/VIAL N18353 001 JUL CAHN -D- + SCS EQ 500MG BASE/VIAL N18353 001 JUL CAHN MIDAZOLAM HYDROCHLORIDE INJECTABLE; INJECTION MIDAZOLAM HCL -A- AP ABBOTT EQ 1MG BASE/ML N75857 001 JUL 22, 2002 JUL NEWA -A- AP EQ 5MG BASE/ML N75857 002 JUL 22, 2002 JUL NEWA MIDODRINE HYDROCHLORIDE TABLET; ORAL PROAMATINE -A- + SHIRE LABS 5MG N19815 002 SEP 06, 1996 JUL CRLD...
|
|
|
Novartis Annual Report 2002
Looking for answers Search Home Financial highlights Letter from Daniel Vasella Amazing Patient Stories...
Division and Product Review Pharmaceuticals Joining Forces in the Quest for Cures Consumer Health Corporate Citizenship Animal Welfare Health, Safety and Environment Human Resources Corporate Governance Financial Report Worldwide Contact Novartis.com - Division and Product...
|
|
|
Pharmaceutical Product List T-Z - Novartis.com
Search Novartis.com - Go Novartis.com Home Products Pharmaceutical Best Sellers Pharmaceuticals CIBA Vision Animal Health Over the Counter Infant and Baby Medical Nutrition Diseases & Conditions About Novartis Investor Relations Media Relations Careers Corporate Citizenship Business Development Our Mission Our Businesses Leadership & Governance Research & Development Foundations...
|
|
|
Tegaserod for irritable bowel syndrome - [Medication] - Quest Diagnostics Patient Health Library
Tegaserod for irritable bowel syndrome Examples Brand Name Chemical Name Zelnorm tegaserod maleate How It Works Tegaserod increases intestinal movement.
Food and Drug Administration (FDA) has recently issued a warning to women taking tegaserod (Zelnorm) for IBS.
Although an increase in gallbladder removal (cholecystectomy) and formation of...
|
|
|
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA 1/ 7 Investor Relations Release Novartis presents positive Phase III data on key compounds and highlights strong late- stage development pipeline · New first- in- class compounds LAF237 (diabetes) and SPP100 (hypertension) set for submission in...
duplicates:
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf page 6
duplicates:
http://www.novartis.com/downloads_new/investors/2005_09_20_Pipeline_Update.pdf
|
|
|
Adult Health Advisor 2004.2: Irritable Bowel Syndrome
Adult Health Topics | All Health Topics Find a UMHS Doctor Search Adult Topics Search All Topics This information is approved and /or reviewed by U-M Health System providers but it is not a tool for self-diagnosis or a substitute for medical treatment.
It's a condition in which the bowel doesn't work as it should.
How does it occur?
What are the symptoms?
Your symptoms...
|
|
|
e_s01_s52_FF12
FACTS & FIGURES 2005 CARING AND CURING ©Novartis AG, July 2005.
Decades of experience and know- how make Sandoz a renowned partner in pharmaceuticals, biogenerics, and anti- infectives.
novartis.
Chairman and CEO Urs Baerlocher, J.
Singh Finance & Administration Thomas van Laar Technical Operations BUSINESS UNIT HEADS David Epstein Specialty Medicines and Oncology...
duplicates:
http://www.novartis.com/downloads/Nov_F_F05_E.pdf
|
|
|
Nov.F&F04_E_12.qxd
FACTS & FIGURES 2004/ 2005 CARING AND CURING 1 OUR MISSION We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life.
CONSUMER HEALTH The Consumer Health Division focuses on creating, developing and manufacturing a wide range of competitively differentiated products that restore, maintain or...
author: comfactory
duplicates:
http://www.novartis.com/downloads/Nov_F_F04_E.pdf
|
|
|
BioPortfolio Limited
Upper GI Disorders - Life Cycle Management Key as Generics and OTC Threaten Growth TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Objective of the analysis 3 Datamonitor insight into the GERD/PUD market 3 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 12 Market definition for this analysis 12 Current market situation 14 Strategic scope and focus 14 Unmet needs in GERD/PUD 15 Onset of...
|
|
|
Novartis Press Kit English page 17
author: guestnc1
duplicates:
http://www.novartis.com/downloads/press_kit.pdf
|
|
|
Novartis Press Kit English page 16
author: guestnc1
duplicates:
http://www.novartis.com/downloads/press_kit.pdf
|
|
|
Database T
T - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
Database Z
Z - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
http://www.novartis.com/downloads_new/about/NOVARTIS_480.pdf
10 Novartis Group Therapeutic area Project/ compound Generic name Indication Cardiovascular Diovan valsartan Congestive heart failure and metabolism Diovan VALIANT valsartan Post- myocardial infarction Lotrel 10TH 40, 5TH 40 benazepril, amlodipine Hypertension Diovan VALUE valsartan High risk hypertension Navigator* valsartan, nateglinide Progression to type- II diabetes Sandostatin...
|
|
|
http://www.novartis.com/downloads_new/about/NOVARTIS_480.pdf page 1
duplicates:
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
|
|
|
Drug Approvals - Z
Product Name Company Application # Approval Date Letter Posted Label Posted Review Posted ZADITOR (ketotifen fumarate ophthalmic solution) 0.025%, Rx Ciba Vision NDA 21-066 7/2/99 7/6/99 7/6/99 3/31/02 ZADITOR (ketotifen fumarate ophthalmic solution) 0.025%, Rx Ciba Vision NDA 21-066/S4 07/20/01 05/08/03 - ZADITOR Indication: for the prevention of itching of the eye due to allergic...
|
|
|
e_UG_s01_s44
Contents Facts & Figures 2003/ 2004 Caring and Curing Contents Overview 01 Who We Are 02 Operations: sales, income and activities 04 Financial and Share Information Businesses 10 Pharmaceuticals 12 Development Pipeline 15 Corporate Research 16 Consumer Health 18 Sandoz 19 OTC 20 Animal Health 21 Medical Nutrition 22 Infant & Baby 23 CIBA Vision Corporate Functions 24 Management 25...
author: mac_36
duplicates:
http://www.novartis.com/downloads_new/news/Novartis%20FactsFigures%202003_2004%20E.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
Novartis Group 1 Overview 2 Financial Highlights 3 News in 2003 Letter from Daniel Vasella 5 The New Number Five in Pharmaceuticals Division and Business Units 9 Pharmaceuticals Giving Thalassemia Patients a Choice Discovering Pharmaceuticals Reliably and Predictably The Long Road to Blood- Pressure Control Treating Breast Cancer Will Never Be the Same Epilepsy Putting Children First...
duplicates:
http://www.novartis.com/downloads_new/investors/ar_2003_e.pdf
|
|
|
Previous News Items 2002
Food and Drug Administration • Center for Drug Evaluation and Research Center for Drug Evaluation and Research Search Previous News Items 2002 Previous News Items 2003 December 20, 2002 FDA approves Gleevec (imatinib mesylate) for the first-line treatment of patients with chronic myeloid leukemia (CML), an uncommon life-threatening form of cancer affecting about 40,000 people in...
author: DLIS
|
